332 CHAPTER 4.2 Table 1. Baseline characteristics of study population. Characteristics N = 139 Age in years, mean (SD) 78.3 (5.1) Gender (Male), N (%) 66 (47.5%) Number of comorbidities, median (IQR) 8 (6-11) Number of prescribed medications (admission), median (IQR) 11 (9-14) Nursing home residents, N (%) 6 (4.3%) Housebound patients, N (%) 19 (13.7%) Barthel Index of ADL, median (IQR) 92.5 (85-100) Patients with ≥1 fall(s) in the past year, N (%) 57 (41.9%) Patients with ≥1 hospital admission in the past year, % 67 (48.2%) Length of stay index hospitalisation in days, median (IQR) 9 (6-18) Estimated GFR (CKD-EPI, mL/min/1.73m2) Mean (SD) 59.1 (20.6) Estimated GFR 30-50 ml/min/1.73m2 N (%) 36 (25.9%) Estimated GFR ≤ 30 ml/min/1.73m2 N (%) 13 (9.4%) Ward (N, %) Medical 109 (78.4) Surgical 30 (21.6) Admission type (N, %) Elective 34 (24.5) Non-elective 105 (75.5) Missing data: number of comorbidities 3 (2.2%) renal function 5 (3.6%) nursing home residents & housebound 1 (0.7%) Barthel Index 1 (0.7%) Falls 3 (2.2%) hospitalisations 1 (0.7%) Agreement with recommendations based on STOPP criteria Among all 237 STOPP recommendations discussed, 146 (61.6%) were agreed upon by both patient and physician. More than half (52.7%) of the STOPP recommendations discussed with the patients and physicians were based on criterion ‘no evidencebased clinical indication’ (STOPP A1), of which there was consensus to discontinue in 60.8% after discussion. Within the STOPP A1 criterion (‘no evidence-based clinical indication’), drugs for acid related disorders (including PPIs) represented 43.2% of the recommendations. After discussion with both patient and attending physician, 74.1% of these recommendations relating to drugs for acid related disorders were agreed upon. Other medication groups within STOPP A1 were heterogeneous and contained
RkJQdWJsaXNoZXIy MTk4NDMw